AFC
VKTX icon

Ares Financial Consulting’s Viking Therapeutics VKTX Stock Holding History

Ares Financial Consulting’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64K Hold
42
– – ﹤0.01% 934
2026
Q1 		$1.38K Hold
42
– – ﹤0.01% 907
2025
Q4 		$1.48K Buy
+42
New +$1.49K ﹤0.01% 712

Other funds holding VKTX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Ares Financial Consulting's VKTX Position: Q2 2026 in Review

Ares Financial Consulting held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 42 shares worth $1.64K. The position accounts for ﹤0.01% of the portfolio, ranked #934.

Ares Financial Consulting first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 166 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Ares Financial Consulting held 42 shares of Viking Therapeutics worth $1.64K as of Q2 2026.
  • Ares Financial Consulting left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #934 holding.
  • Ares Financial Consulting first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 166 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.